WO2008146178A2 - A novel tablet dosage form - Google Patents
A novel tablet dosage form Download PDFInfo
- Publication number
- WO2008146178A2 WO2008146178A2 PCT/IB2008/051092 IB2008051092W WO2008146178A2 WO 2008146178 A2 WO2008146178 A2 WO 2008146178A2 IB 2008051092 W IB2008051092 W IB 2008051092W WO 2008146178 A2 WO2008146178 A2 WO 2008146178A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- agents
- pharmaceutically acceptable
- cellulose
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system.
- the dosage form includes a first layer that includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable ex- cipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
- EP1091731 discloses a dosage form that includes a non-steroidal anti-inflammatory drug (NSAID) in coated pellets and misoprostol is located outside the pellets in the form of a solid dispersion in hydroxypropyl methyl- cellulose or polyvinylpyrrolidone.
- NSAID non-steroidal anti-inflammatory drug
- NSAID selected from diclofenac and piroxicam, which core is surrounded by a mantle coating of a prostaglandin such as misoprostol, wherein an intermediate coating can be present between the NSAID core and prostaglandin mantle coating.
- NSAID selected from diclofenac and piroxicam, a prostaglandin such as misoprostol, and a stabilizer, preferably hydroxypropyl methylcellulose.
- U.S. Patents Nos. 6,183,779 and 6,287,600 disclose a dosage form that includes an
- NSAID present in enteric-coated granules or particles and misoprostol is located outside the pellets in the form of a solid dispersion in hydroxypropyl methylcellulose or polyvinylpyrrolidone.
- U.S. Patents Nos. 6,387,410; 6,514,525; 6,537,582 and 6,787,155 disclose a similar dosage form that includes the NSAID containing pellets in a delayed release formulation.
- U.S. Application No. 2005163847 discloses a solid dosage form that includes a first portion comprising NSAID; and a coating containing an antiulcerative compound, said coating at least partially surrounding the NSAID portion.
- Non-steroidal anti-inflammatory drugs present a great therapeutic benefit in the treatment of inflammatory conditions such as arthritis, but have an ulcerogenic effect in the upper gastrointestinal tract, which can seriously limit their usefulness, especially for chronic treatment.
- Certain prostaglandin type compounds, especially prostaglandin El derivatives and more particularly, misoprostol have been found to mitigate or provide protection against such ulcerogenic effects when co-administered with an NSAID.
- prostaglandin type compounds particularly prostaglandin El derivatives such as misoprostol
- the primary pathway of degradation is believed to be dehydration to the corresponding prostaglandin A derivative.
- the problem of chemical instability becomes more acute when the prostaglandin type compound is co formulated with certain NSAIDs such as diclofenac or piroxicam.
- a tablet dosage form in one general aspect there is provided a tablet dosage form.
- the dosage form includes a layer that includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable ex- cipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
- the dosage form may include a coating.
- the tablet may be coated with one or more enteric polymers; pharmaceutically acceptable seal coat polymers or rate controlling polymers.
- the tablet may form a bilayered tablet.
- active ingredient' refers to a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates and solvates of the compound and the prodrugs.
- the pharmaceutically acceptable excipients may include one or more of binders, fillers, antioxidants, disintegrants, surfactants, lubricants and glidants and the like.
- the dosage form may be made by a comprising of compressing a) first layer comprising of tablets of one or more active pharmaceutical ingredients with inert pharmaceutically acceptable excipients; and b) the second layer comprising of one or more active pharmaceutical ingredients along with inert pharmaceutically acceptable excipients into bilayered tablet dosage form.
- a tablet dosage form in another general aspect there is provided a tablet dosage form.
- the dosage form includes a layer that includes a tablet of diclofenac or a salt thereof, wherein the tablet is inlayed in said layer with other pharmaceutically acceptable excipients and another layer that includes misoprostol or a salt thereof and optionally other pharmaceutically acceptable excipients.
- the term 'inlayed in said layer' is used herein to mean that the tablet of diclofenac or a salt thereof may be present at any position in said layer.
- Embodiments of the dosage form may include one or more of the following features.
- the dosage form may exhibit a dissolution profile such that within first 2 hours less than 2% of diclofenac or a salt thereof is released when the release rate is measured in Apparatus 2 (USP, Dissolution, paddle, 50 rpm) using 900 ml of 0.1N HCl at 37 0 C ⁇ 0.5 0 C and within first 30 minutes more than 75% of diclofenac or a salt thereof is released, when the release rate is measured in Apparatus 2 (USP, Dissolution, paddle, 50 rpm) using 900 ml of pH 6.8 phosphate buffer at 37 0 C + 0.5 0 C.
- the dosage form may include a coating.
- the tablet may be coated with one or more enteric polymers or pharmaceutically acceptable seal coat polymers.
- the tablet may form a bilayered tablet.
- the pharmaceutically acceptable excipients may include one or more of binders, fillers, antioxidants, disintegrants, surfactants, lubricants and glidants and the like.
- Figure 1 shows some of the examples of tablet dosage form of the invention.
- the dosage form includes a first layer that includes a tablet of one or more active pharmaceutical ingredients, which is inlay ed in the first layer along with inert pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
- misoprostol when misoprostol is not in a direct contact with diclofenac and outer environmental conditions, misoprostol is not degraded and a stable formulation can be prepared.
- diclofenac tablet when diclofenac tablet is inlayed in one layer along with inert pharmaceutically acceptable excipients, it is not in direct contact with misoprostol, which is present in another layer. Hence, misoprostol is prevented from degradation.
- the inlayed tablet may be prepared by mixing at least one active ingredient optionally with other inert pharmaceutically acceptable excipients to form a premix, optionally converting the premix into granules and compressing the premix or granules into tablets.
- the inlayed tablet may include a coating.
- the tablet may be coated with one or more enteric polymers, pharmaceutically acceptable seal coat polymers or rate controlling polymers.
- the one or more active pharmaceutical ingredients may be one or more of antiinflammatory agents, sedatives, hypnotics, antibiotics, antidiabetics, antihypertensives, anti-osteoporosis agents, antithrombotic agents, antivirals, antifungals, anticholinergic agents, anxiolytic agents, adrenergics, antipsychotics, anti-parkinsonism agents, anticonvulsants, antiepileptics, CNS stimulants, antianginal agents, antiarrhythmics, anti- hyperlipidemic drugs, diuretics, antiasthmatics, anticoagulants, antianemia agents, vitamins, hormones, antihistaminics, anticancer agents, antiallergics, antiarthritis agents, antialzheimers' agents, vasopressin antagonists, anticonvulsants, steroids, anesthetics, thrombolytics, antacids, proton pump inhibitors, protease inhibitors, platelet aggregation inhibitors,
- the one or more active pharmaceutical ingredients may be one or more of am- lodipine, diazepam, paracetamol, aspirin, ciprofloxacin, dicyclomine, celecoxib, alendronate, diacerein, acyclovir, fluconazole, epinephrine, divalproex, methyl- phenidate, flecainide, metoprolol, fenofibrate, hydrochlorothiazide, montelukast, heparin, warfarin, hemoglobin, iron, ascorbic acid, leutinizing hormone, bicalutamide, donepezil, tolvaptan, cortisones, lidocaine, calcium carbonate, saquinavir, bromhexine, promethazine, bisacodyl, pancreatin, ethinyl estradiol, salbutamol, diphenhydramine, sumatriptan, diclofenac,
- the active ingredient present in one or both layers of the dosage form may be present in an immediate release, delayed release, sustained release, extended release, controlled release or modified release form.
- one or both layers may include one or more rate controlling polymers.
- Suitable rate controlling polymers may include one or more of hydrophilic or hydrophobic polymers such as polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, shellac, rosin, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, hydroxypropyl cellulose, hydroxypropyl methyl- cellulose, carboxy vinyl polymers, and the like.
- hydrophilic or hydrophobic polymers such as poly
- the dosage form of the present invention may be made by a comprising of compressing a) first layer comprising of tablets of one or more active pharmaceutical in- gredients with inert pharmaceutically acceptable excipients; and b) the second layer comprising of one or more active pharmaceutical ingredients along with inert pharmaceutically acceptable excipients into bilayered tablet dosage form.
- diclofenac and misoprostol dosage form may be prepared by compressing tablets of diclofenac or a salt thereof and the misoprostol blend in such a way that the tablets of diclofenac or a salt thereof is inlayed at any position in one layer with other pharmaceutically acceptable excipients and misoprostol blend is compressed in another layer resulting in a bilayered tablet dosage form.
- the tablets of diclofenac or a salt thereof may be prepared by mixing diclofenac or a salt thereof optionally with other pharmaceutically acceptable excipients to form a premix, optionally converting the premix into granules by dry granulation or wet granulation and compressing the premix or granules into tablets. Further, this tablet may optionally be coated with a seal coat polymer followed by enteric coating with pharmaceutically acceptable enteric coating polymers.
- One layer of the diclofenac misoprostol tablet of the invention includes a diclofenac tablet inlayed at any position in said layer along with other pharmaceutically acceptable excipients and other layer includes misoprostol polymer dispersion in a mixture with other pharmaceutically acceptable excipients.
- the polymer in the misoprostol-polymer dispersion may be one or more of hy- droxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, and the like.
- Suitable pharmaceutically acceptable enteric coating polymers may include one or more of methacrylic acid/methyl methacrylate copolymers such as Eudragits or cellulose derivatives such as carboxymethyl cellulose, cellulose acetate phthalate, hy- droxypropylmethyl cellulose phthalate, and other suitable polymers.
- the dosage forms as described herein may include other pharmaceutically acceptable excipients.
- examples of other pharmaceutically acceptable as used herein may include binders, fillers, antioxidants, disintegrants, surfactants, lubricants and glidants.
- Suitable binders may include one or more of, povidone, starch, stearic acid, gums, hydroxypropylmethyl cellulose, and the like.
- Suitable fillers may include one or more of, microcrystalline cellulose, lactose, mannitol, calcium phosphate, calcium sulfate, kaolin, dry starch, powdered sugar, and the like.
- Suitable antioxidants may include one or more of dibutylhydroxy toluene (BHT), propyl gallate, butylhydroxyanisole (BHA), ⁇ -tocopherol, citric acid, and the like.
- BHT dibutylhydroxy toluene
- BHA butylhydroxyanisole
- Suitable disintegrants may include one or more of starch, croscarmellose sodium, crospovidone, sodium starch glycolate, and the like.
- Diclofenac sodium was mixed with microcrystalline cellulose, lactose, povidone, and sodium starch glycollate in a double cone blender to form a pre-mix.
- the pre-mix was further mixed with povidone and converted into flakes by compacting it through a roll compactor.
- the flakes were sized into granules, which were then lubricated with magnesium stearate in a double cone blender, and the lubricated granules were compressed into tablets using a suitable tooling.
- the compressed tablets were further seal coated with hypromellose polyethylene glycol solution in water.
- the seal coated diclofenac sodium tablets were coated with enteric polymer suspension prepared by mixing methacrylic acid polymer, sodium hydroxide, talc, triethyl citrate in water. Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a double cone blender.
- Benazepril was mixed with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide in a suitable blender. The above mixture was lubricated with talc in a suitable blender to form the benazepril blend.
- Amlodipine was mixed with microcrystalline cellulose, lactose, pregelatinized starch, in a suitable blender to form a pre-mix. The pre-mix was further mixed with crospovidone and converted into flakes by compacting it through a suitable compactor.
- Example 3 The flakes were sized into granules, which were then lubricated with magnesium stearate in a suitable blender, and the lubricated granules were compressed into tablets using a suitable tooling.
- Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a suitable blender.
- the amlodipine tablets were compressed along with inert excipients and benazepril blend in such a way that the amlodipine tablet was inlayed at any position in the first layer along with inert excipients and the benazepril blend was compressed as a second layer to form a bilayered tablet dosage form.
- Example 3 Example 3
- Telmisartan was mixed with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide in a suitable blender. The above mixture was lubricated with talc in a suitable blender to form the telmisartan blend.
- Amlodipine was mixed with microcrystalline cellulose, lactose, pregelatinized starch, in a suitable blender to form a pre-mix. The pre-mix was further mixed with crospovidone and converted into flakes by compacting it through a suitable compactor.
- Example 4 The flakes were sized into granules, which were then lubricated with magnesium stearate in a suitable blender, and the lubricated granules were compressed into tablets using a suitable tooling.
- Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a suitable blender.
- the amlodipine tablets were compressed along with inert excipients and the telmisartan blend in such a way that the amlodipine tablet was inlayed at any position in the first layer along with inert excipients and the telmisartan blend was compressed as a second layer to form a bilayered tablet dosage form.
- Example 4 Example 4
- Atorvastatin was mixed with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide in a suitable blender. The above mixture was lubricated with talc in a suitable blender to form the atorvastatin blend.
- Amlodipine was mixed with microcrystalline cellulose, lactose, pregelatinized starch, in a suitable blender to form a pre-mix.
- the pre-mix was further mixed with crospovidone and converted into flakes by compacting it through a suitable compactor.
- the flakes were sized into granules, which were then lubricated with magnesium stearate in a suitable blender, and the lubricated granules were compressed into tablets using a suitable tooling.
- Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a suitable blender.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
Description
Description A NOVEL TABLET DOSAGE FORM
[ 1 ] Field of the Invention
[2] The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer that includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable ex- cipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
[3] Background of the Invention
[4] There is an ever-increasing desire for combining active ingredients belonging to different therapeutic categories. However, instability of the active ingredients poses a major obstacle in combining these active ingredients in a single dosage form. Drug instability is the phenomenon, which occurs when the effects of one drug are modified by the presence of another drug in the same dosage form. Therefore, combination dosage form which combines the features of pharmacologic efficacy, adequate drug stability, and a reliable and robust method of manufacture has to overcome a number of technical problems to be formulated in a single dosage form. Further, the standard approach of directly mixing the active ingredients with the necessary excipients cannot be applied to combination products of different active ingredients and more sophisticated techniques are needed to separate the different active ingredients in a single dosage form.
[5] There are various types of combination products dosage forms conceivable but it cannot be predicted which of these dosage forms best combines product stability, pharmacological efficacy, and a reliable manufacturing method. It is an object of the present invention to provide a novel tablet dosage form, which can encompass drugs of different classes which otherwise pose stability issues in a single unit.
[6] There are several references known in the literature, which describe different techniques/methods/dosage forms combining different drugs in one unit dosage form.
[7] International Publication No. (PCT) WO 2007/043061 discloses a tablet-in-tablet system wherein two chemically incompatible anti-malarial compounds are separated by a film coating.
[8] European Patent Application No. EP1216030A1 discloses a dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaglandin and one or more excipients.
[9] European Patent Application No. EP1091731 discloses a dosage form that includes a
non-steroidal anti-inflammatory drug (NSAID) in coated pellets and misoprostol is located outside the pellets in the form of a solid dispersion in hydroxypropyl methyl- cellulose or polyvinylpyrrolidone.
[10] U.S. Patents Nos. 5,601,843 and 5,698,225 disclose a tablet having a core of a
NSAID selected from diclofenac and piroxicam, which core is surrounded by a mantle coating of a prostaglandin such as misoprostol, wherein an intermediate coating can be present between the NSAID core and prostaglandin mantle coating.
[11] U.S. Patent No. 5,015,481 describes compositions that include an admixture of an
NSAID selected from diclofenac and piroxicam, a prostaglandin such as misoprostol, and a stabilizer, preferably hydroxypropyl methylcellulose.
[12] U.S. Patents Nos. 6,183,779 and 6,287,600 disclose a dosage form that includes an
NSAID present in enteric-coated granules or particles and misoprostol is located outside the pellets in the form of a solid dispersion in hydroxypropyl methylcellulose or polyvinylpyrrolidone. U.S. Patents Nos. 6,387,410; 6,514,525; 6,537,582 and 6,787,155 disclose a similar dosage form that includes the NSAID containing pellets in a delayed release formulation.
[13] U.S. Patent No. 5,232,704 discloses a capsule dosage form containing one layer that includes a drug release layer containing misoprostol and the other a buoyant or floating layer.
[14] U.S. Application No. 2005163847 discloses a solid dosage form that includes a first portion comprising NSAID; and a coating containing an antiulcerative compound, said coating at least partially surrounding the NSAID portion.
[15] Non-steroidal anti-inflammatory drugs (NSAIDs) present a great therapeutic benefit in the treatment of inflammatory conditions such as arthritis, but have an ulcerogenic effect in the upper gastrointestinal tract, which can seriously limit their usefulness, especially for chronic treatment. Certain prostaglandin type compounds, especially prostaglandin El derivatives and more particularly, misoprostol have been found to mitigate or provide protection against such ulcerogenic effects when co-administered with an NSAID.
[16] Chemical degradation of certain prostaglandin type compounds, particularly prostaglandin El derivatives such as misoprostol, is accelerated in the presence of water, and the primary pathway of degradation is believed to be dehydration to the corresponding prostaglandin A derivative. The problem of chemical instability becomes more acute when the prostaglandin type compound is co formulated with certain NSAIDs such as diclofenac or piroxicam.
[17] The present invention addresses and overcomes these commonly encountered problems.
[18] Summary of the Invention
[19] In one general aspect there is provided a tablet dosage form. The dosage form includes a layer that includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable ex- cipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
[20] The dosage form may include a coating. The tablet may be coated with one or more enteric polymers; pharmaceutically acceptable seal coat polymers or rate controlling polymers. The tablet may form a bilayered tablet.
[21] The term 'active ingredient' refers to a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates and solvates of the compound and the prodrugs.
[22] The pharmaceutically acceptable excipients may include one or more of binders, fillers, antioxidants, disintegrants, surfactants, lubricants and glidants and the like.
[23] In another general aspect there is provided a process of making dosage form. The dosage form may be made by a comprising of compressing a) first layer comprising of tablets of one or more active pharmaceutical ingredients with inert pharmaceutically acceptable excipients; and b) the second layer comprising of one or more active pharmaceutical ingredients along with inert pharmaceutically acceptable excipients into bilayered tablet dosage form.
[24] In another general aspect there is provided a tablet dosage form. The dosage form includes a layer that includes a tablet of diclofenac or a salt thereof, wherein the tablet is inlayed in said layer with other pharmaceutically acceptable excipients and another layer that includes misoprostol or a salt thereof and optionally other pharmaceutically acceptable excipients.
[25] The term 'inlayed in said layer' is used herein to mean that the tablet of diclofenac or a salt thereof may be present at any position in said layer.
[26] Embodiments of the dosage form may include one or more of the following features.
For example, the dosage form may exhibit a dissolution profile such that within first 2 hours less than 2% of diclofenac or a salt thereof is released when the release rate is measured in Apparatus 2 (USP, Dissolution, paddle, 50 rpm) using 900 ml of 0.1N HCl at 37 0C ± 0.50C and within first 30 minutes more than 75% of diclofenac or a salt thereof is released, when the release rate is measured in Apparatus 2 (USP, Dissolution, paddle, 50 rpm) using 900 ml of pH 6.8 phosphate buffer at 37 0C + 0.50C.
[27] The dosage form may include a coating. The tablet may be coated with one or more enteric polymers or pharmaceutically acceptable seal coat polymers. The tablet may form a bilayered tablet.
[28] The pharmaceutically acceptable excipients may include one or more of binders, fillers, antioxidants, disintegrants, surfactants, lubricants and glidants and the like.
[29] The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
[30] Description of the Drawings
[31] Figure 1 shows some of the examples of tablet dosage form of the invention.
[32] Detailed Description of the Invention
[33] As described above with respect to the difficulties associated with different classes of pharmaceutical active ingredients, which pose stability issues when present in a single unit system, there exists a need for universally applicable, unit dosage form or system. These difficulties are believed to be addressed by the techniques and concepts described herein. The present inventors have now discovered a novel tablet dosage form, which prevents a direct contact of one active ingredient with another ingredient thus leading to a stable system. The dosage form includes a first layer that includes a tablet of one or more active pharmaceutical ingredients, which is inlay ed in the first layer along with inert pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
[34] The inventors have now discovered that when misoprostol is not in a direct contact with diclofenac and outer environmental conditions, misoprostol is not degraded and a stable formulation can be prepared. According to one embodiment, when diclofenac tablet is inlayed in one layer along with inert pharmaceutically acceptable excipients, it is not in direct contact with misoprostol, which is present in another layer. Hence, misoprostol is prevented from degradation.
[35] The inlayed tablet may be prepared by mixing at least one active ingredient optionally with other inert pharmaceutically acceptable excipients to form a premix, optionally converting the premix into granules and compressing the premix or granules into tablets. The inlayed tablet may include a coating. The tablet may be coated with one or more enteric polymers, pharmaceutically acceptable seal coat polymers or rate controlling polymers.
[36] The one or more active pharmaceutical ingredients may be one or more of antiinflammatory agents, sedatives, hypnotics, antibiotics, antidiabetics, antihypertensives, anti-osteoporosis agents, antithrombotic agents, antivirals, antifungals, anticholinergic agents, anxiolytic agents, adrenergics, antipsychotics, anti-parkinsonism agents, anticonvulsants, antiepileptics, CNS stimulants, antianginal agents, antiarrhythmics, anti- hyperlipidemic drugs, diuretics, antiasthmatics, anticoagulants, antianemia agents, vitamins, hormones, antihistaminics, anticancer agents, antiallergics, antiarthritis agents, antialzheimers' agents, vasopressin antagonists, anticonvulsants, steroids, anesthetics, thrombolytics, antacids, proton pump inhibitors, protease inhibitors, platelet
aggregation inhibitors, mucolytics, antimalarials, antiemetics, laxatives, expectorants, enzymes, contraceptives, bronchodilators, antitussives, antimigraine agents, anthelmintics, and anorexiants.
[37] The one or more active pharmaceutical ingredients may be one or more of am- lodipine, diazepam, paracetamol, aspirin, ciprofloxacin, dicyclomine, celecoxib, alendronate, diacerein, acyclovir, fluconazole, epinephrine, divalproex, methyl- phenidate, flecainide, metoprolol, fenofibrate, hydrochlorothiazide, montelukast, heparin, warfarin, hemoglobin, iron, ascorbic acid, leutinizing hormone, bicalutamide, donepezil, tolvaptan, cortisones, lidocaine, calcium carbonate, saquinavir, bromhexine, promethazine, bisacodyl, pancreatin, ethinyl estradiol, salbutamol, diphenhydramine, sumatriptan, diclofenac, metronidazole, orlistat, ibuprofen, indomethacin, ketorolac, tramadolol, oxcarbazepine, pioglitazone, rosiglitazone, miglitol, vildagliptin, sitagliptin, repaglinide, voglibose, alprazolam, chlorpromazine, cimetidine, pseudoephedrine, naproxen, piroxicam, atenolol, benazepril, captopril, lisinopril, fosinopril, enalapril, furosemide, indapamide, atenolol, felodipine, verapamil, cartenolol, carvedilol, cerivastatin, diltiazem, fluvastatin, irbesartan, candesartan, methyldopa, reserpine, bupropion, fluoxetine, paroxetine, escitalopram, sertraline, amitryptiline, imipramine, fexofenadine, clopidogrel, entacapone, levodopa, carbidopa, levetiracetam, venlafaxine, duloxetine, lisinopril, losartan, lovastatin, niacin, pravastatin, ramipril, simvastatin, atorvastatin, valsartan, telmisartan, sildenafil, tadalafil, vardenafil, esomeprazole, famotidine, omeprazole, pantoprazole, rabeprazole, ranitidine, simethicone, artesunate, amodiaquine, benazepril, misoprostol, metformin, glipizide, and their pharmaceutically acceptable salts.
[38] The active ingredient present in one or both layers of the dosage form may be present in an immediate release, delayed release, sustained release, extended release, controlled release or modified release form.
[39] In general, one or both layers may include one or more rate controlling polymers.
Suitable rate controlling polymers may include one or more of hydrophilic or hydrophobic polymers such as polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, shellac, rosin, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, hydroxypropyl cellulose, hydroxypropyl methyl- cellulose, carboxy vinyl polymers, and the like.
[40] The dosage form of the present invention may be made by a comprising of compressing a) first layer comprising of tablets of one or more active pharmaceutical in-
gredients with inert pharmaceutically acceptable excipients; and b) the second layer comprising of one or more active pharmaceutical ingredients along with inert pharmaceutically acceptable excipients into bilayered tablet dosage form.
[41] In one embodiment, diclofenac and misoprostol dosage form may be prepared by compressing tablets of diclofenac or a salt thereof and the misoprostol blend in such a way that the tablets of diclofenac or a salt thereof is inlayed at any position in one layer with other pharmaceutically acceptable excipients and misoprostol blend is compressed in another layer resulting in a bilayered tablet dosage form.
[42] The tablets of diclofenac or a salt thereof may be prepared by mixing diclofenac or a salt thereof optionally with other pharmaceutically acceptable excipients to form a premix, optionally converting the premix into granules by dry granulation or wet granulation and compressing the premix or granules into tablets. Further, this tablet may optionally be coated with a seal coat polymer followed by enteric coating with pharmaceutically acceptable enteric coating polymers.
[43] One layer of the diclofenac misoprostol tablet of the invention includes a diclofenac tablet inlayed at any position in said layer along with other pharmaceutically acceptable excipients and other layer includes misoprostol polymer dispersion in a mixture with other pharmaceutically acceptable excipients.
[44] The polymer in the misoprostol-polymer dispersion may be one or more of hy- droxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, and the like.
[45] Suitable pharmaceutically acceptable seal coat polymers may include one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose and other suitable cellulose ethers.
[46] Suitable pharmaceutically acceptable enteric coating polymers may include one or more of methacrylic acid/methyl methacrylate copolymers such as Eudragits or cellulose derivatives such as carboxymethyl cellulose, cellulose acetate phthalate, hy- droxypropylmethyl cellulose phthalate, and other suitable polymers.
[47] The dosage forms as described herein may include other pharmaceutically acceptable excipients. Examples of other pharmaceutically acceptable as used herein may include binders, fillers, antioxidants, disintegrants, surfactants, lubricants and glidants.
[48] Suitable binders may include one or more of, povidone, starch, stearic acid, gums, hydroxypropylmethyl cellulose, and the like.
[49] Suitable fillers may include one or more of, microcrystalline cellulose, lactose, mannitol, calcium phosphate, calcium sulfate, kaolin, dry starch, powdered sugar, and the like.
[50] Suitable antioxidants may include one or more of dibutylhydroxy toluene (BHT), propyl gallate, butylhydroxyanisole (BHA), α-tocopherol, citric acid, and the like.
[51] Suitable disintegrants may include one or more of starch, croscarmellose sodium, crospovidone, sodium starch glycolate, and the like. [52] Suitable surfactants may be anionic, non-ionic or cationic and may include one or more of polyoxyethylene hardened castor oil, glycerin monostearate, sorbitan mono- stearate, sorbitan monopalmitate, sorbitan monolaurate, a polyoxyethylene poly- oxypropylene block copolymer, polysorbates, sodium lauryl sulfate, macrogols, sucrose fatty acid ester, and the like. [53] Suitable lubricants may include one or more of magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, and the like. [54] Suitable glidants may include one or more of colloidal silicon dioxide, talc or cornstarch, and the like. [55] While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. [56] Example 1
[57] Table 1
[58]
[59] Procedure: Misoprostol-hypromellose dispersion was mixed with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide in a double cone blender. The above mixture was lubricated with pre-sifted hydrogenated castor oil in a double cone blender to form the misoprostol blend.
[60] Diclofenac sodium was mixed with microcrystalline cellulose, lactose, povidone, and sodium starch glycollate in a double cone blender to form a pre-mix. The pre-mix was further mixed with povidone and converted into flakes by compacting it through a roll compactor. The flakes were sized into granules, which were then lubricated with magnesium stearate in a double cone blender, and the lubricated granules were compressed into tablets using a suitable tooling.
[61] The compressed tablets were further seal coated with hypromellose polyethylene glycol solution in water. The seal coated diclofenac sodium tablets were coated with enteric polymer suspension prepared by mixing methacrylic acid polymer, sodium hydroxide, talc, triethyl citrate in water. Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a double cone blender.
[62] The enteric-coated diclofenac sodium tablets were compressed along with inert excipients and the misoprostol blend in such a way that diclofenac sodium tablet was inlayed at any position in the first layer along with inert excipients and the misoprostol blend was compressed as a second layer to form a bilayered tablet dosage form. Finally, the bilayered tablet was further coated with an aqueous dispersion of Opadry.
[63] Example 2 [64] Table 2 [65]
[Table 2] [Table ]
[66] Procedure: Benazepril was mixed with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide in a suitable blender. The above mixture was lubricated with
talc in a suitable blender to form the benazepril blend. [67] Amlodipine was mixed with microcrystalline cellulose, lactose, pregelatinized starch, in a suitable blender to form a pre-mix. The pre-mix was further mixed with crospovidone and converted into flakes by compacting it through a suitable compactor.
The flakes were sized into granules, which were then lubricated with magnesium stearate in a suitable blender, and the lubricated granules were compressed into tablets using a suitable tooling. [68] Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a suitable blender. [69] The amlodipine tablets were compressed along with inert excipients and benazepril blend in such a way that the amlodipine tablet was inlayed at any position in the first layer along with inert excipients and the benazepril blend was compressed as a second layer to form a bilayered tablet dosage form. [70] Example 3
[71] Table 3
[72]
[Table 3] [Table ]
[73] Procedure: Telmisartan was mixed with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide in a suitable blender. The above mixture was lubricated
with talc in a suitable blender to form the telmisartan blend. [74] Amlodipine was mixed with microcrystalline cellulose, lactose, pregelatinized starch, in a suitable blender to form a pre-mix. The pre-mix was further mixed with crospovidone and converted into flakes by compacting it through a suitable compactor.
The flakes were sized into granules, which were then lubricated with magnesium stearate in a suitable blender, and the lubricated granules were compressed into tablets using a suitable tooling. [75] Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a suitable blender. [76] The amlodipine tablets were compressed along with inert excipients and the telmisartan blend in such a way that the amlodipine tablet was inlayed at any position in the first layer along with inert excipients and the telmisartan blend was compressed as a second layer to form a bilayered tablet dosage form. [77] Example 4
[78] Table 4
[79]
[Table 4] [Table ]
[80] Procedure: Atorvastatin was mixed with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide in a suitable blender. The above mixture was lubricated
with talc in a suitable blender to form the atorvastatin blend.
[81] Amlodipine was mixed with microcrystalline cellulose, lactose, pregelatinized starch, in a suitable blender to form a pre-mix. The pre-mix was further mixed with crospovidone and converted into flakes by compacting it through a suitable compactor. The flakes were sized into granules, which were then lubricated with magnesium stearate in a suitable blender, and the lubricated granules were compressed into tablets using a suitable tooling.
[82] Inert excipients like crospovidone, colloidal silicon dioxide, sodium starch glycollate, microcrystalline cellulose and hydrogenated castor oil were mixed together in a suitable blender.
[83] The amlodipine tablets were compressed along with inert excipients and the atorvastatin blend in such a way that the amlodipine tablet was inlayed at any position in the first layer along with inert excipients and the atorvastatin blend was compressed as a second layer to form a bilayered tablet dosage form.
[84] While the invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention.
Claims
Claims
[1] A tablet dosage form comprising: a) a first layer comprising a tablet of one or more active pharmaceutical ingredients, wherein the tablet is inlay ed in the first layer with one or more other pharmaceutically acceptable excipients; and b) a second layer comprising or more active pharmaceutical ingredients and optionally other pharmaceutically acceptable excipients.
The dosage form of claim 1, wherein the one or more active pharmaceutical ingredients is present in an immediate release, delayed release, sustained release, extended release, controlled release or modified release form. The dosage form of claim 1, wherein the dosage form comprises a bilayered dosage form.
The dosage form of claim 1, further comprising coating the tablet with one or more enteric polymers, pharmaceutically acceptable seal coat polymers or rate controlling polymers.
The dosage form of claim 4, wherein the enteric polymer comprises one or more of methacrylic acid/methyl methacrylate copolymers, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, polyvinyl acetate phthalate, and cellulose acetate trimellitate. The dosage form of claim 4, wherein the pharmaceutically acceptable seal coat polymer comprises one or more of hydroxypropyl methylcellulose, hy- droxypropyl cellulose and cellulose ethers.
The dosage form of claim 4, wherein the rate-controlling polymer comprises one or more of hydrophilic and hydrophobic polymers.
The dosage form of claim 7, wherein the rate controlling polymer comprises one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, shellac, rosin, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly (ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and carboxy vinyl polymers.
9. The dosage form of claim 1, wherein the one or more active pharmaceutical ingredients comprise one or more of anti-inflammatory agents, sedatives, hypnotics, antibiotics, antidiabetics, antihypertensives, anti-osteoporosis agents,
antithrombotic agents, antivirals, antifungals, anticholinergic agents, anxiolytic agents, adrenergics, antipsychotics, anti-parkinsonism agents, anticonvulsants, antiepileptics, CNS stimulants, antianginal agents, antiarrhythmics, antihyper- lipidemic drugs, diuretics, antiasthmatics, anticoagulants, antianemia agents, vitamins, hormones, antihistaminics, anticancer agents, antiallergics, antiarthritis agents, antialzheimers' agents, vasopressin antagonists, anticonvulsants, steroids, anesthetics, thrombolytics, antacids, proton pump inhibitors, protease inhibitors, platelet aggregation inhibitors, mucolytics, antimalarials, antiemetics, laxatives, expectorants, enzymes, contraceptives, bronchodilators, antitussives, antimigraine agents, anthelmintics, and anorexiants.
The dosage form of claim 9, wherein the one or more active pharmaceutical ingredients comprise one or more of amlodipine, diazepam, paracetamol, aspirin, ciprofloxacin, dicyclomine, celecoxib, alendronate, diacerein, acyclovir, fluconazole, epinephrine, divalproex, methylphenidate, flecainide, metoprolol, fenofibrate, hydrochlorothiazide, montelukast, heparin, warfarin, hemoglobin, iron, ascorbic acid, leutinizing hormone, bicalutamide, donepezil, tolvaptan, cortisones, lidocaine, calcium carbonate, saquinavir, bromhexine, promethazine, bisacodyl, pancreatin, ethinyl estradiol, salbutamol, diphenhydramine, sumatriptan, diclofenac, metronidazole, orlistat, ibuprofen, indomethacin, ketorolac, tramadolol, oxcarbazepine, pioglitazone, rosiglitazone, miglitol, vildagliptin, sitagliptin, repaglinide, voglibose, alprazolam, chlorpromazine, ci- metidine, pseudoephedrine, naproxen, piroxicam, atenolol, benazepril, captopril, lisinopril, fosinopril, enalapril, furosemide, indapamide, atenolol, felodipine, verapamil, cartenolol, carvedilol, cerivastatin, diltiazem, fluvastatin, irbesartan, candesartan, methyldopa, reserpine, bupropion, fluoxetine, paroxetine, es- citalopram, sertraline, amitryptiline, imipramine, fexofenadine, clopidogrel, en- tacapone, levodopa, carbidopa, levetiracetam, venlafaxine, duloxetine, lisinopril, losartan, lovastatin, niacin, pravastatin, ramipril, simvastatin, atorvastatin, valsartan, telmisartan, sildenafil, tadalafil, vardenafil, esomeprazole, famotidine, omeprazole, pantoprazole, rabeprazole, ranitidine, simethicone, artesunate, amo- diaquine, benazepril, misoprostol, metformin, glipizide, and their pharmaceutically acceptable salts.
The dosage form of claim 1, wherein the one or more active pharmaceutical ingredients comprise one or both of diclofenac and misoprostol or their pharmaceutically acceptable salts.
The dosage form of claim 1, wherein the pharmaceutically acceptable excipients comprise one or more of binders, fillers, antioxidants, disintegrants, surfactants, lubricants and glidants.
A tablet dosage form comprising: a) a first layer comprising a tablet of diclofenac or a salt thereof, wherein the tablet is inlayed in the first layer with other pharmaceutically acceptable ex- cipients; and b) a second layer comprising misoprostol or a salt thereof and optionally other pharmaceutically acceptable excipients.
The dosage form of claim 13, further comprising coating the tablet with one or more enteric polymers or pharmaceutically acceptable seal coat polymers. The dosage form of claim 14, wherein the enteric polymer comprises one or more of methacrylic acid/methyl methacrylate copolymers, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, polyvinyl acetate phthalate, and cellulose acetate tri- mellitate.
The dosage form of claim 14, wherein the pharmaceutically acceptable seal coat polymer comprises one or more of hydroxypropyl methylcellulose, hy- droxypropyl cellulose and cellulose ethers.
The dosage form of claim 13, wherein the dosage form exhibits a dissolution profile such that within first 2 hours less than 2% of diclofenac or a salt thereof is released, when the release rate is measured in Apparatus 2 (USP, Dissolution, paddle, 50 rpm) using 900 ml of 0. IN HCl at 37 0C + 0.50C and within first 30 minutes more than 75% of diclofenac or a salt thereof is released, when the release rate is measured in Apparatus 2 (USP, Dissolution, paddle, 50 rpm) using 900 ml of pH 6.8 phosphate buffer at 37 0C + 0.50C.
The dosage form of claim 13, wherein the pharmaceutically acceptable excipients comprise one or more ofbinders, fillers, antioxidants, solubilizing agents, dis integrants, surfactants, lubricants and glidants.
The dosage form of claim 13, wherein the dosage form comprises a bilayered dosage form.
A process of preparing pharmaceutical composition, which process comprises of compressing a) first layer comprising of tablets of one or more active pharmaceutical ingredients with inert pharmaceutically acceptable excipients; and b) the second layer comprising of one or more active pharmaceutical ingredients along with inert pharmaceutically acceptable excipients into tablet dosage form.
The process of claim 20, wherein the one or more active pharmaceutical ingredients is present in an immediate release, delayed release, sustained release, extended release, controlled release or modified release form.
The process of claim 20, wherein the dosage form comprises a bilayered dosage form.
The process of claim 20, further comprising coating the tablet with one or more enteric polymers, pharmaceutically acceptable seal coat polymers or rate controlling polymers.
The process of claim 23, wherein the enteric polymer comprises one or more of methacrylic acid/methyl methacrylate copolymers, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, polyvinyl acetate phthalate, and cellulose acetate trimellitate. The process of claim 23, wherein the pharmaceutically acceptable seal coat polymer comprises one or more of hydroxypropyl methylcellulose, hy- droxypropyl cellulose and cellulose ethers.
The process of claim 23, wherein the rate-controlling polymer comprises one or more of hydrophilic and hydrophobic polymers.
The process of claim 26, wherein the rate controlling polymer comprises one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, shellac, rosin, zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and carboxyvinyl polymers. 28. The process of claim 20, wherein the one or more active pharmaceutical ingredients comprise one or more of anti-inflammatory agents, sedatives, hypnotics, antibiotics, antidiabetics, antihypertensives, anti-osteoporosis agents, antithrombotic agents, antivirals, antifungals, anticholinergic agents, anxiolytic agents, adrenergics, antipsychotics, anti-parkinsonism agents, anticonvulsants, antiepileptics, CNS stimulants, antianginal agents, antiarrhythmics, antihyper- lipidemic drugs, diuretics, antiasthmatics, anticoagulants, antianemia agents, vitamins, hormones, antihistaminics, anticancer agents, antiallergics, antiarthritis agents, antialzheimers' agents, vasopressin antagonists, anticonvulsants, steroids, anesthetics, thrombolytics, antacids, proton pump inhibitors, protease inhibitors, platelet aggregation inhibitors, mucolytics, antimalarials, antiemetics, laxatives, expectorants, enzymes, contraceptives, bronchodilators, antitussives, antimigraine agents, anthelmintics, and anorexiants.
The process of claim 28, wherein the one or more active pharmaceutical ingredients comprise one or more of amlodipine, diazepam, paracetamol, aspirin,
ciprofloxacin, dicyclomine, celecoxib, alendronate, diacerein, acyclovir, fluconazole, epinephrine, divalproex, methylphenidate, flecainide, metoprolol, fenofibrate, hydrochlorothiazide, montelukast, heparin, warfarin, hemoglobin, iron, ascorbic acid, leutinizing hormone, bicalutamide, donepezil, tolvaptan, cortisones, lidocaine, calcium carbonate, saquinavir, bromhexine, promethazine, bisacodyl, pancreatin, ethinyl estradiol, salbutamol, diphenhydramine, sumatriptan, diclofenac, metronidazole, orlistat, ibuprofen, indomethacin, ketorolac, tramadolol, oxcarbazepine, pioglitazone, rosiglitazone, miglitol, vildagliptin, sitagliptin, repaglinide, voglibose, alprazolam, chlorpromazine, ci- metidine, pseudoephedrine, naproxen, piroxicam, atenolol, benazepril, captopril, lisinopril, fosinopril, enalapril, furosemide, indapamide, atenolol, felodipine, verapamil, cartenolol, carvedilol, cerivastatin, diltiazem, fluvastatin, irbesartan, candesartan, methyldopa, reserpine, bupropion, fluoxetine, paroxetine, es- citalopram, sertraline, amitryptiline, imipramine, fexofenadine, clopidogrel, en- tacapone, levodopa, carbidopa, levetiracetam, venlafaxine, duloxetine, lisinopril, losartan, lovastatin, niacin, pravastatin, ramipril, simvastatin, atorvastatin, valsartan, telmisartan, sildenafil, tadalafil, vardenafil, esomeprazole, famotidine, omeprazole, pantoprazole, rabeprazole, ranitidine, simethicone, artesunate, amo- diaquine, benazepril, misoprostol, metformin, glipizide, and their pharmaceutically acceptable salts.
The process of claim 20, wherein the one or more active pharmaceutical ingredients comprise one or both of diclofenac and misoprostol or their pharmaceutically acceptable salts.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/602,168 US8574625B2 (en) | 2007-05-30 | 2008-03-25 | Tablet dosage form |
EP08737626.5A EP2167048B1 (en) | 2007-05-30 | 2008-03-25 | A novel tablet dosage form |
US14/026,106 US9408806B2 (en) | 2007-05-30 | 2013-09-13 | Tablet dosage form |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1006MU2007 | 2007-05-30 | ||
IN1006/MUM/2007 | 2007-05-30 | ||
IN558/MUM/2008 | 2008-03-19 | ||
IN558MU2008 | 2008-03-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/602,168 A-371-Of-International US8574625B2 (en) | 2007-05-30 | 2008-03-25 | Tablet dosage form |
US14/026,106 Continuation US9408806B2 (en) | 2007-05-30 | 2013-09-13 | Tablet dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008146178A2 true WO2008146178A2 (en) | 2008-12-04 |
WO2008146178A3 WO2008146178A3 (en) | 2009-03-19 |
Family
ID=39884707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/051092 WO2008146178A2 (en) | 2007-05-30 | 2008-03-25 | A novel tablet dosage form |
Country Status (3)
Country | Link |
---|---|
US (2) | US8574625B2 (en) |
EP (1) | EP2167048B1 (en) |
WO (1) | WO2008146178A2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010089772A3 (en) * | 2009-01-22 | 2010-10-14 | Piramal Healthcare Ltd. | Chronotherapeutic pharmaceutical composition |
CN101919864A (en) * | 2010-06-21 | 2010-12-22 | 天津市汉康医药生物技术有限公司 | Tolvaptan medicinal composition and preparation method thereof |
EP2316435A1 (en) * | 2009-10-22 | 2011-05-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine |
EP2377521A1 (en) | 2010-03-26 | 2011-10-19 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of telmisartan and diuretic combination |
WO2012055941A1 (en) | 2010-10-27 | 2012-05-03 | Krka,Tovarna Zdravil, D. D., Novo Mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
WO2012005500A3 (en) * | 2010-07-06 | 2012-05-03 | 주식회사 네비팜 | Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration |
EP2468361A1 (en) * | 2010-12-21 | 2012-06-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Vildagliptin Formulations |
EP2698147A1 (en) * | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral Film Formulations Comprising Dapoxetine and Tadalafil |
EP2698148A1 (en) * | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Chewing Gum Formulations Comprising Dapoxetine and Tadalafil |
EP2698146A1 (en) * | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Tablet Formulations Comprising Tadalafil and Dapoxetine |
CN104825449A (en) * | 2014-02-12 | 2015-08-12 | 天津药物研究院 | Compound composition containing atorvastatin calcium and amlodipine and preparation method of same |
BE1023116B1 (en) * | 2015-07-24 | 2016-11-23 | Nordic Specialty Pharma Bvba | PARACETAMOL COMPRISING PREPARATION WITH DELAYED AND CONTINUOUS ISSUE |
AU2013349898B2 (en) * | 2012-11-23 | 2018-05-10 | Gnosis S.P.A. | Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states |
EP3285754A4 (en) * | 2015-04-20 | 2018-12-19 | TWI Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
CN110124053A (en) * | 2019-06-13 | 2019-08-16 | 扬州大学 | A kind of synthetic method and its drug of heparin Allan sodium phosphate conjugate |
EP4295839A1 (en) * | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010522135A (en) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
JP5714910B2 (en) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
AU2009223061B2 (en) | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
CN103327994B (en) * | 2010-11-04 | 2016-06-01 | 盖尼奥斯生物医学国际公司 | A kind of compositions preparation for treat or reduce carcinoma of prostate in subject seriousness medicine in application |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
CN102366412B (en) * | 2011-10-21 | 2013-05-15 | 四川百利药业有限责任公司 | Preparation method of tolvaptan tablet |
AU2012349771A1 (en) * | 2011-12-09 | 2014-07-03 | Wockhardt Limited | Methods for treating cardiovascular disorder |
MX356789B (en) * | 2013-01-16 | 2018-06-12 | Invekra S A P I De C V | Prolonged-release diphenidol composition. |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9579257B2 (en) | 2013-08-20 | 2017-02-28 | Anutra Medical, Inc. | Haptic feedback and audible output syringe |
KR101663238B1 (en) * | 2013-11-15 | 2016-10-14 | 한미약품 주식회사 | Complex solid formulation comprising tadalafil and amlodipine |
KR102229798B1 (en) * | 2013-12-12 | 2021-03-19 | 한미약품 주식회사 | Bilayered tablet composite formulation comprising metformin and losartan |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
US20160008371A1 (en) * | 2014-07-14 | 2016-01-14 | Autotelic Llc | Fixed dose combination for pain relief without edema |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
CN104546691B (en) * | 2015-01-28 | 2019-01-15 | 中国药科大学 | A kind of joint cavity injection thermosensitive in-situ gel preparation composition and preparation method thereof |
KR102158339B1 (en) * | 2016-02-05 | 2020-09-21 | 삼진제약주식회사 | Carvedilol immediate release formulation having improved madescent |
US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
CN107224585B (en) * | 2016-03-25 | 2020-10-27 | 南京优科制药有限公司 | A composition comprising a non-steroidal anti-inflammatory drug and a proton pump inhibitor |
CN105796524B (en) * | 2016-03-29 | 2019-01-01 | 山西兰花药业股份有限公司 | A kind of aspirin enteric coated tablet |
US10350171B2 (en) * | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
CA3069948C (en) * | 2017-07-17 | 2022-05-17 | Eli Lilly And Company | A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin |
CN107213138B (en) * | 2017-08-07 | 2020-12-18 | 北京罗诺强施医药技术研发中心有限公司 | Method and pharmaceutical composition for treating hypertension by timed release of drugs |
CN107669683B (en) * | 2017-09-30 | 2020-07-03 | 杭州华东医药集团新药研究院有限公司 | Pharmaceutical composition containing sitagliptin and metformin |
TWI812649B (en) * | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
KR102034694B1 (en) * | 2017-12-14 | 2019-10-22 | 한국유나이티드제약 주식회사 | Cored tablet comprising mosapride and rabeprazole |
JP2019218313A (en) * | 2018-06-21 | 2019-12-26 | 沢井製薬株式会社 | Sustained-release preparation containing pseudoephedrine or pharmaceutically acceptable salt thereof |
JP2021536467A (en) | 2018-09-06 | 2021-12-27 | インノファーマスクリーン インコーポレイテッド | Methods and compositions for the treatment of asthma or Parkinson's disease |
MX2018011142A (en) | 2018-09-13 | 2019-10-10 | Federico Amezcua Amezcua | A synergistic pharmaceutical combination of a selective cyclloxygenasa-2 inhibitor and an antraquinone derivative. |
CN108904495B (en) * | 2018-09-29 | 2021-04-13 | 哈尔滨珍宝制药有限公司 | Levetiracetam pharmaceutical composition and preparation method and application thereof |
US11325872B2 (en) * | 2019-06-17 | 2022-05-10 | Total Grow LLO | Concentrated aqueous suspension of microfibrillated cellulose comprising salts for plant nutrition |
US20210275531A1 (en) * | 2020-03-04 | 2021-09-09 | VK Research Associates Inc | Phosphodiesterase-5 inhibitor combinations, methods of making, and methods of use thereof |
CN112618526A (en) * | 2021-01-11 | 2021-04-09 | 重庆康刻尔制药股份有限公司 | Compound preparation for treating diabetes complicated with hypertension and preparation method thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015481A (en) | 1990-05-03 | 1991-05-14 | G. D. Searle & Co. | Stabilized pharmaceutical admixture composition |
US5232704A (en) | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
US5601843A (en) | 1990-05-03 | 1997-02-11 | G. D. Searle & Co. | Pharmaceutical tablet composition |
US6183779B1 (en) | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
EP1091731A1 (en) | 1998-07-01 | 2001-04-18 | Norton Healthcare Limited | Anti-inflammatory pharmaceutical formulations |
US6387410B1 (en) | 1998-09-10 | 2002-05-14 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
EP1216030A1 (en) | 1999-10-01 | 2002-06-26 | Norton Healthcare Limited | Anti-inflammatory pharmaceutical formulations |
US6514525B2 (en) | 1998-09-10 | 2003-02-04 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
US20050163847A1 (en) | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
WO2007043061A1 (en) | 2005-10-11 | 2007-04-19 | Ipca Laboratories Ltd. | Anti-malarial combination and methods of formulation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2241342C (en) * | 1998-06-15 | 2000-02-08 | Bernard Charles Sherman | Pharmaceutical tablets comprising an nsaid and a prostaglandin |
CA2259727A1 (en) | 1999-01-18 | 2000-07-18 | Bernard Charles Sherman | A two-layer pharmaceutical tablet comprising an nsaid and misoprostol |
ES2244326B1 (en) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | COMBINATION OF ACTIVE SUBSTANCES. |
DE102006035549A1 (en) * | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Pharmaceutical form with at least two-layer separating layer |
-
2008
- 2008-03-25 EP EP08737626.5A patent/EP2167048B1/en not_active Not-in-force
- 2008-03-25 US US12/602,168 patent/US8574625B2/en not_active Expired - Fee Related
- 2008-03-25 WO PCT/IB2008/051092 patent/WO2008146178A2/en active Application Filing
-
2013
- 2013-09-13 US US14/026,106 patent/US9408806B2/en not_active Expired - Fee Related
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5601843A (en) | 1990-05-03 | 1997-02-11 | G. D. Searle & Co. | Pharmaceutical tablet composition |
US5698225A (en) | 1990-05-03 | 1997-12-16 | G. D. Searle & Co. | Pharmaceutical composition |
US5015481A (en) | 1990-05-03 | 1991-05-14 | G. D. Searle & Co. | Stabilized pharmaceutical admixture composition |
US5232704A (en) | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
EP1091731A1 (en) | 1998-07-01 | 2001-04-18 | Norton Healthcare Limited | Anti-inflammatory pharmaceutical formulations |
US6514525B2 (en) | 1998-09-10 | 2003-02-04 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
US6387410B1 (en) | 1998-09-10 | 2002-05-14 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
US6537582B2 (en) | 1998-09-10 | 2003-03-25 | Norton Healthcare Ltd. | Anti-inflammatory pharmaceutical formulations |
US6787155B2 (en) | 1998-09-10 | 2004-09-07 | Norton Healthcare Ltd. | Anti-inflammatory pharmaceutical formulations |
US6287600B1 (en) | 1999-03-22 | 2001-09-11 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
US6183779B1 (en) | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
EP1216030A1 (en) | 1999-10-01 | 2002-06-26 | Norton Healthcare Limited | Anti-inflammatory pharmaceutical formulations |
US20050163847A1 (en) | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
WO2007043061A1 (en) | 2005-10-11 | 2007-04-19 | Ipca Laboratories Ltd. | Anti-malarial combination and methods of formulation |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102316864A (en) * | 2009-01-22 | 2012-01-11 | 雅培医疗保健私人有限公司 | The chronotherapy pharmaceutical composition |
WO2010089772A3 (en) * | 2009-01-22 | 2010-10-14 | Piramal Healthcare Ltd. | Chronotherapeutic pharmaceutical composition |
EP2316435A1 (en) * | 2009-10-22 | 2011-05-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine |
WO2011048553A3 (en) * | 2009-10-22 | 2011-08-25 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of pde-5 inhibitors and dapoxetine |
EP2377521A1 (en) | 2010-03-26 | 2011-10-19 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of telmisartan and diuretic combination |
CN101919864A (en) * | 2010-06-21 | 2010-12-22 | 天津市汉康医药生物技术有限公司 | Tolvaptan medicinal composition and preparation method thereof |
WO2012005500A3 (en) * | 2010-07-06 | 2012-05-03 | 주식회사 네비팜 | Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration |
EA025946B1 (en) * | 2010-10-27 | 2017-02-28 | Крка, Товарна Здравил, Д. Д., Ново Место | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
WO2012055941A1 (en) | 2010-10-27 | 2012-05-03 | Krka,Tovarna Zdravil, D. D., Novo Mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
TR201010683A1 (en) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formulations. |
EP2468361A1 (en) * | 2010-12-21 | 2012-06-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Vildagliptin Formulations |
EP2698147A1 (en) * | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral Film Formulations Comprising Dapoxetine and Tadalafil |
EP2698148A1 (en) * | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Chewing Gum Formulations Comprising Dapoxetine and Tadalafil |
EP2698146A1 (en) * | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Tablet Formulations Comprising Tadalafil and Dapoxetine |
WO2014027978A1 (en) * | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Chewing gum formulations comprising dapoxetine and tadalafil |
WO2014027980A1 (en) * | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
WO2014027979A3 (en) * | 2012-08-17 | 2014-05-15 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tablet formulations comprising tadalafil and dapoxetine |
AU2013349898B2 (en) * | 2012-11-23 | 2018-05-10 | Gnosis S.P.A. | Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states |
CN104825449A (en) * | 2014-02-12 | 2015-08-12 | 天津药物研究院 | Compound composition containing atorvastatin calcium and amlodipine and preparation method of same |
EP3285754A4 (en) * | 2015-04-20 | 2018-12-19 | TWI Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
BE1023116B1 (en) * | 2015-07-24 | 2016-11-23 | Nordic Specialty Pharma Bvba | PARACETAMOL COMPRISING PREPARATION WITH DELAYED AND CONTINUOUS ISSUE |
CN110124053A (en) * | 2019-06-13 | 2019-08-16 | 扬州大学 | A kind of synthetic method and its drug of heparin Allan sodium phosphate conjugate |
EP4295839A1 (en) * | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
WO2023247435A1 (en) * | 2022-06-20 | 2023-12-28 | Krka, D.D., Novo Mesto | Bilayer tablets of valsartan and indapamide |
Also Published As
Publication number | Publication date |
---|---|
EP2167048B1 (en) | 2016-10-26 |
US20100196471A1 (en) | 2010-08-05 |
US20160213620A9 (en) | 2016-07-28 |
US8574625B2 (en) | 2013-11-05 |
WO2008146178A3 (en) | 2009-03-19 |
US20150079170A1 (en) | 2015-03-19 |
EP2167048A2 (en) | 2010-03-31 |
US9408806B2 (en) | 2016-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2167048B1 (en) | A novel tablet dosage form | |
AU700949B2 (en) | New beads for controlled release and a pharmaceutical preparation containing the same | |
US20120207825A1 (en) | Pharmaceutical compositions for reducing alcohol-induced dose dumping | |
US6319519B2 (en) | Anti-inflammatory pharmaceutical formulations | |
AU725493B2 (en) | Lozenge for the modified release of active compounds in the gastrointestinal tract | |
EP2373319B1 (en) | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof | |
EP1886665A1 (en) | Gastro retentive delivery system | |
CA2792046C (en) | Modified release dosage form | |
MXPA05006916A (en) | Modified release pharmaceutical composition. | |
WO2010048478A2 (en) | Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates | |
JP2010540547A (en) | Gallenus formulation of aliskiren and valsartan | |
EP1091731B1 (en) | Anti-inflammatory pharmaceutical formulations | |
WO2007086079B1 (en) | Sustained release dosage form of phenothiazine derivatives containing channelizer | |
AU747046B2 (en) | Pharmaceutical tablets comprising an NSAID and a prostaglandin | |
CA2648495C (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
MXPA06010805A (en) | Clarithromycin extended release formulation. | |
WO2011080716A2 (en) | Pharmaceutical composition for modified delivery of actives | |
US20100136111A1 (en) | Pharmaceutical compositions of diclofenac and misoprostol | |
WO2009047800A2 (en) | Oral controlled release composition of carvedilol | |
JP2008507587A (en) | Dosage form with enteric coated core tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08737626 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2008737626 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008737626 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12602168 Country of ref document: US |